Table of Contents Table of Contents
Previous Page  462 / 1082 Next Page
Information
Show Menu
Previous Page 462 / 1082 Next Page
Page Background

S447

ESTRO 36 2017

_______________________________________________________________________________________________

anterior descending artery (LAD), and the thyroid, were

compared to those of non-coplanar 3D-CRT and coplanar

VMAT. A p value < 0.05, derived using the paired Student’s

t-test, was considered to reflect a significant difference.

Results

Figure 1-B shows the averaged dose-volume histograms for

all 24 patients in terms of their PTVs and OARs. The Table

summarizes the mean dose volume indices for the targets

and OARs, and the MU for each technique. Significant

difference was not observed in doses to the PTV. When

DWA was employed, the average V

20Gy

, V

10Gy

, and V

5Gy

to

the ipsilateral lung; the average V

10Gy

and V

5Gy

to the heart;

the D

2%

for the planning organ at risk volume of the LAD

(PRV_LAD); and the V

50%

of, and the mean dose to the

ipsilateral breast, were significantly lower than those of

non-coplanar 3D-CRT and coplanar VMAT. The average D

2%

to the contralateral breast and the V

5Gy

to the

contralateral lung did not differ significantly among the

techniques. Furthermore, the mean prescribed MU for

DWA was 486.22 MU, which was only 9.8% higher than that

for non-coplanar 3D-CRT (442.67 MU) (p < 0.05).

Conclusion

The use of DWA for APBI improved the dose distribution

compared to that of non-coplanar 3D-CRT and coplanar

VMAT; this may reduce the risk of toxicity without

prolonging treatment time.

PO-0838 Treatment planning for the MR-linac: plan

quality compared with current clinical practice

A.J.A.J. Van de Schoot

1

, C. Carbaat

1

, B. Van Triest

1

, T.M.

Janssen

1

, J.J. Sonke

1

1

The Netherlands Cancer Institute, Department of

Radiation Oncology, Amsterdam, The Netherlands

Purpose or Objective

Clinical introduction of the MR-linac (MRL) involves

treatment planning using Monaco (Elekta AB, Stockholm,